Generic supplier gets in the celebrity marketing game

Share this article:
Celebrities signing on as spokespeople for branded pharmaceuticals is nothing new, but now a generic drug supplier is getting in the game.

Genmed Holding Corp has hired actor Eric Roberts to talk up Genmed and its “work to bring the most basic of generic medications to well over 6 billion people worldwide who currently do not have access to the most basic of drugs,” according to a company release. Roberts, best known for his roles in Pope of Greenwich Village and Runaway Train, for which he was nominated for an Oscar, sang Genmed's praises on Access Hollywood Live yesterday morning and will appear in the firm's as-yet unspecified 2011 marketing campaigns and video news releases.

Genmed distributes 69 FDA-approved generics in non-EU countries and hopes to register, distribute and market 17 of those products in 12 EU countries within three years. The US and Netherlands-based company says current sales volume for its target markets, including the EU and developing markets, is around 9.4 billion Euros.

Roberts, also known as Julia Roberts' older brother, presumably will not be talking up medical marijuana, having recently kicked the evil weed on Dr. Drew's VH1 show Celebrity Rehab.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...